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Objective: To study echocardiographic parameters
of left ventricular systolic function and valvar regurgita-
tion under pharmacological influence in mildly sympto-
matic patients with chronic mitral regurgitation (MR).
Methods: We carried out a double-blind placebo con-
trolled study in 12 patients with MR, mean aged 12.5 years
old, who were randomized in 4 phases: A) digoxin; B)
enalapril; C) digoxin + enalapril; D) placebo. The medi-
cation was administered for 30 days in each phase, and the
following variables were analyzed: shortening and ejection
fractions, wall stress index of left ventricle, left ventricular
meridional end-systolic wall stress, Doppler-derived mean
rate of left ventricular pressure rise (mean dP/dt), stroke
volume and MR jet area. The clinical variables analysed
were heart rate and systemic arterial pressure.
Results: No significant variation was observed in the
clinical variables analysed. The shortening and ejection
fraction, the mean dP/dt and stroke volume significantly
increased and the wall stress index of left ventricle, the me-
ridional left ventricular end systolic wall stress and the
mitral regurgitation jet area decreased in the phases with
medication as compared with that in the placebo phase.
Conclusion: The parameters of left ventricular
systolic function improved significantly and the degree of
MR decreased with the isolated administration of digoxin
or enalapril in mildly symptomatic patients with chronic
MR. The combination of the drugs, however, did not show
better results.
Key words: echocardiography, left ventricular function,
mitral regurgitation
Arq Bras Cardiol, volume 80 (nº 2), 144-9, 2003
Ivan Romero Rivera, Valdir Ambrósio Moisés, Antonio Carlos Carvalho, Angelo Amato V. de Paola
São Paulo, SP - Brazil
Mildly Symptomatic Chronic Mitral Regurgitation. Analysis
of Left Ventricular Systolic Function and Mitral Regurgitant
Fraction Under Pharmacological Influence.
Echocardiographic Study
Original Article
Mitral regurgitation with a rheumatic etiology is a fre-
quent problem in developing countries 1. Although the cli-
nical treatment has been well established for symptomatic
patients or patients with left ventricular dysfunction 2, the
same has not happened with asymptomatic or mildly sym-
ptomatic patients with mitral regurgitation with hemody-
namic repercussion, who have been empirically medicated
with digitalis or vasodilators, or both.
Although these drugs have confirmed usefulness in
situations in which heart failure becomes evident 3,4, their
efficacy in individuals with preserved ventricular function,
and, therefore, asymptomatic or mildly symptomatic, has
not yet been well defined.
No middle- or long-term studies exist analyzing the
response of ventricular function parameters to the pharma-
cological effects of digitalis or vasodilators, or both, in chil-
dren and adolescents with chronic mitral regurgitation and
preserved ventricular function. The few data available are
related to studies in healthy adults 5, in patients with mitral
regurgitation secondary to cardiomyopathy 3,4, and in
adults with mildly symptomatic mitral regurgitation of
different etiologies, both with a single dose 6,7 or with pro-
longed medication 8-13.
The major aim of this study was to analyze the behavior
of some ventricular function parameters and the degree of
valvular regurgitation under the prolonged use of digitalis
and enalapril in mildly symptomatic children and adolescents
with chronic mitral regurgitation with a rheumatic etiology.
Methods
The study comprised mildly symptomatic patients
(NYHA FC I – II) with chronic mitral valvular regurgitation
clinically detected or detected on echocardiography. The
hemodynamic repercussion, defined as the dilation of the
cardiac chambers due to valvular regurgitation, was consi-
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The exclusion criteria were: presence of rheumatic acti-
vity in the 6 months preceding the beginning of the study or
laboratory tests compatible with the acute phase of the
disease; myocardial disease of any etiology; systemic or
congenital disease, or both; pulmonary or systemic arterial
hypertension, or both; multivalvular disease or associated
mitral stenosis. The exclusion criteria during the study were
as follows: worsening of the patient's functional class;
symptomatic arterial hypotension; acute rheumatic fever
clinically detected or detected through laboratory tests, or
both, or alterations in the laboratory tests due to the use of
medication, or both.
Penicillin benzathine was maintained in all patients.
After 15 days of no oral medication, the patients underwent
clinical examination, 12-lead electrocardiography, chest X-
ray, echocardiography and cardiopulmonary exercise testing.
They were then randomized into 4 phases: A: digoxin + pla-
cebo; B: enalapril + placebo; C: digoxin + enalapril; and D:
placebo + placebo. Because it was a double-blind study, the
medication was always combined with a placebo to avoid the
recognition of phase C. Randomization was performed in a
way that each phase always had 3 patients, and, at the end of
the study, the 12 patients had passed the 4 phases (fig. 1).
The medication was administered for 30 days in each
phase, as follows: a) digoxin – if weight < 25kg = 10 mcg/kg/
day, if weight > 25kg = 0.25mg/day; b) enalapril maleate – if
weight < 25kg = 0.2mg/kg/day, if weight > 25kg = 5mg/day.
This was a prospective double-blind study, the drugs were
used for 30 days, and the washout period lasted 10 days.
The mean duration of the study was 150 days and the pa-
tients were clinically assessed every 10 days, and assessed
with laboratory tests (ESR, ASO, PCR, and serum creatinine,
sodium, and potassium) every 15 days.
An echocardiographic study was performed at the be-
ginning and end of each phase. After a 15-minute rest, the
patient's heart rate and blood pressure were measured, and,
immediately afterwards, the examination began. Based on
data of systolic and diastolic blood pressure, the mean
blood pressure was calculated with the following formula:
MBP = [(SBP-DBP)/3] + DBP.
The echocardiographic images were obtained with the
Ultramark 7 device (Advanced Technology Laboratories,
USA) and a 2.5-mHz transducer, equipped with pulsed Dop-
pler (PD), continuous Doppler (CD), and color flow map-
ping. The longitudinal and transverse parasternal views
and the apical 2-chamber and 4-chamber views were used.
Heart rate was monitored during the study with an electro-
cardiographic lead. On the first examination, the exact posi-
tion of the transducer to be used in the subsequent exami-
nations was determined, as was the size of the volume
sample for the examinations with pulsed Doppler (1 mm). On
color flow mapping, the Nyquist limit of 61 cm/s was esta-
blished for all patients, and the gain level to be used for each
patient in the subsequent examinations was defined as that
situated immediately below the “static noise” level in the
image of the first examination. The examinations were
recorded on videotapes for further analysis and all measu-
rements obtained were evaluated in 5 consecutive heart
beats during the expiratory phase of breathing by 2 obser-
vers; a mean was used for the calculation. After a complete
2-dimensional examination with the patient in the left lateral
decubitus position, the following parameters were asses-
sed on M mode: left ventricular diastolic and systolic dia-
meters, and diastolic and systolic thickness of the interven-
tricular septum and of the posterior wall as recommended
by the American Society of Echocardiography 14.
For determining the ejection fraction, the left ventricu-
lar end-diastolic and end-systolic volumes were calculated
according to the following formula: Vol = [7/(2.4 + D)] D3 15,
in which D is the left ventricular diameter in cm, the result
being expressed in cm3. The stroke volume was calculated
according to the formula: SV = VTI x CSA, in which VTI is
the velocity-time integral of the aortic flow obtained with
pulsed Doppler immediately below the aortic valve in the
apical 4-chamber view, and CSA is the cross-sectional area
calculated at the same place in the longitudinal parasternal
view 16. The result was expressed in cm3. Valvular regurgi-
tation was quantified by color flow mapping in the longitu-
dinal, transverse, and apical 2- and 4-chamber views with
the mean of the results being used for calculating the regur-
gitant fraction (RF % = regurgitant jet area/left atrial area) 17.
Left ventricular systolic function was quantified with
the shortening fraction (DD% = [(DD - SD)/DD] x 100) 18 and
the ejection fraction (EF% = [(DVol - SVol)/DVol] x 100) 19.
Left ventricular end-systolic wall stress (Wss = SBP x R/h)
expressed in mm Hg was calculated, as was left ventricular
end-systolic meridional wall stress 20,21 (ESWS = (SBP x D x
1.35)/ (h) (1 + h/D)(4) expressed in g/cm2. In these formulas,
Fig. 1 – Sketch showing the methodology used in the examinations in the different phases
o
Phases Phases Phases Phases
A A A A
B B B B
* 1 C 1 * 2 C 1 * 2 C 1 * 2 C
or or or or
D D D D
15 days 30 days 10 days 30 days 10 days 30 days 10 days 30 days
(o)- Randomization; (*)- period with no medication; 1- clinical examination, electrocardiography, chest X-ray, echocardiography, and cardiopulmonary exercise test;
2- clinical examination and echocardiography.
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SBP is systolic systemic blood pressure, D is the left ventri-
cular systolic diameter, h is the systolic wall thickness, 1.35
is the converting factor from mm Hg to g/cm2, and R is the
left ventricular systolic radius (D/2).
The incremental rate of left ventricular pressure in res-
pect to time, or mean left ventricular dP/dt, was also calcula-
ted 22 based on a curve of mitral regurgitation velocity
obtained with cardiac output oriented by color flow map-
ping in apical 4-chamber view. The time necessary for a
variation of 32 mm Hg in left ventricular pressure (velocity
of 1 m/seg to 4 m/seg) was calculated in milliseconds, and
this time was used as the denominator of the relation dP/dt =
(32 mm Hg/t) x 1000. With this objective, the regurgitation
curves with the best definition of the borders were selected,
and a difference of up to 20 mm Hg between the systolic
peak of the curve and the patient’s systolic blood pressure
was accepted as valid.
All patients underwent a complete echocardiographic
examination at the beginning of the study, which was used
as a model in subsequent examinations. If the measurements
in the different subsequent examinations had a variation
greater than 10%, new measurements were performed to
confirm the findings, and, therefore, to avoid intrinsic varia-
tions depending on the position of the transducer. To test
the inter- and intraobserver variability, 10 examinations were
randomly chosen, and the results obtained by the 2 obser-
vers participating in the study were compared.
The Wilcoxon test was used for analyzing ventricular
function, stroke volume, and regurgitant fraction. The
paired t test was used for analyzing the left ventricular sys-
tolic and diastolic diameters, heart rate, and blood pressure.
The interphase variability was studied by using D% =
[(Post – Pre)/Pre] x 100, and the results were analyzed with
the Friedman test comparing D% A x D% B x D% C x D% D;
the results with significant differences were compared with
the multiple comparisons procedure. The cardiothoracic
ratio was analyzed with the Friedman test. The statistical
significance level of p £ 0.05 was adopted. The inter- and in-
traobserver variabilities were studied with the correlation
coefficient using linear regression analysis.
Results
We prospectively studied 12 patients (9 females) with
a mean age of 12.5±2.4 years (6-15 years) and body surface
between 0.79 and 1.63 m2, who had chronic mitral regurgita-
tion with a rheumatic etiology (outpatient care unit follow-
up ³ 6 months) with hemodynamic repercussion. Nine
patients were in NYHA functional class I, and 3 patients
were in NYHA functional class II. All patients were recei-
ving penicillin benzathine, and the 3 in functional class II
were taking 10 mcg/kg/day of digoxin.
At the beginning of the study, the mean diastolic dia-
meter on echocardiography was 58.6 mm (51 to 73 mm) cor-
responding to an increase of 12 to 55% in the superior limit
of the data standardized for body surface by the American
Society of Echocardiography 23; the mean systolic diameter
was 36.6 mm (31 to 47 mm); the mean DD% was 38.08% (34 to
42%); and the mean ejection fraction was 67.25% (62 to
72%). All patients had sinus rhythm on the electrocardio-
gram and a cardiothoracic ratio between 0.35 and 0.59 on
chest X-ray (tab. I).
Clinically, no alteration in functional class existed, no
patient was excluded from the study and all patients passed
though the 4 phases. No change in the electrocardiographic
findings was observed when analyzing the QRS complex,
the ventricular repolarization or the QT interval. The chest
X-ray showed no evident alteration in the pulmonary flow
pattern, and the cardiothoracic ratio had no significant
variation. The mean values in the different phases were as
follows: Pre = 0.47; A = 0.46; B = 0.46; C = 0.47; and D = 0.47.
Heart rate, systolic, diastolic, and mean blood pres-
sures, and left ventricular diastolic diameter showed no sig-
nificant variation when the pre- and postdata were compa-
red in the different phases (tab. II).
The end-systolic diameter showed a significant re-
duction in the phases A, B, and C, and no significant varia-
Table I – Characteristics of the patients in baseline conditions distributed according to age, functional class, weight, body surface, blood pressure, and
echocardiographic data
P t Age FC weight BS BP ECG CTR Echocardiogram
DD SD
01 10 I 41 1.33 120x70 Sin/LAO 0.45 55 32
02 13 I 43 1.43 110x70 Sin/LAO 0.46 73 47
03 14 I 51 1.55 120x80 Sin/Nl 0.44 57 34
04 12 I 33 1.15 104x74 Sin/LAO 0.45 51 31
05 14 I 40 1.33 130x70 Sin/Nl 0.48 56 35
06 11 II 26 1.02 100x70 Sin/LAO 0.59 60 36
07 15 I 49 1.46 130x80 Sin/LAO 0.45 55 37
08 13 II 50 1.42 120x80 Sin/LAO 0.55 65 39
09 06 I 20 0.79 90x60 Sin/LAO 0.52 59 35
10 14 I 55 1.55 114x80 Sin/LAO 0.44 57 36
11 13 I 62 1.63 106x70 Sin/LAO 0.35 56 35
12 15 II 49 1.52 114x76 Sin/LAO 0.45 64 42
Pt - patient; FC - functional class; BS – body surface; BP – systemic blood pressure; ECG - electrocardiogram; Sin – sinus rhythm; LAO – left atrial overload; Nl –
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tion in phase D (A: p=0.01; B: p=0.005; C: p=0.0004; D:
p=0.7). The multiple comparisons test showed that phase C
was the most different from the placebo phase, ie, C > D. The
shortening fraction (DD%) had a significant increase in
phases B and C, and the ejection fraction (EF%) in phases
A, B, and C, with no significant variation in phase D (A:
p=0.1 and p=0.04; B: p=0.002 and p=0.002; C: p=0.001 and
p=0.001; D: p=0.55 and p=0.64, respectively). The multiple
comparisons test showed that phases B and C were the
most different from the placebo phase, ie, B and C > D. The
mean dP/dt showed a significant increase in phases A, B,
and C, with a mild reduction in phase D (A: p=0.002; B:
p=0.01; C: p=0.001; D: p=0.8). The multiple comparisons test
showed that phases A and C were the most different from
the placebo phase, ie, A and C > D. Both left ventricular end-
systolic meridional wall stress (ESWS) and left ventricular
end-systolic wall stress (Wss) showed significant reduction
in phases A, B, and C, and a mild increase in phase D (A:
p=0.007 and p=0.007; B: p=0.003 and p=0.005; C: p=0.009
and p=0.01; D: p=0.3 and p=0.3, respectively). The stroke
volume showed an increase in phases A, B, and C, and a re-
duction in phase D; this increase, however, was only signi-
ficant in phase A (A: p=0.03; B: p=0.2; C: p=0.4; D: p=0.3).
Both the regurgitant fraction and the regurgitant jet area
showed reductions in phases A, B, and C, and no variation
in phase D.  This reduction, however, was only significant in
phase A (A: p=0.03 and 0.04; B: p=0.07 and 0.07; C: p=0.1
and 0.2; D: p=0.8 and 0.9, respectively). The mean values of
each parameter studied distributed in the different phases of
the study are shown in table II.
Nine patients underwent the cardiopulmonary exer-
cise test. Of the 12 patients studied, 2 did not undergo that
test due to technical difficulties as follows: the first patient
could not pedal due to lack of adaptation, and the second
patient was short-statured, and, therefore, could not un-
dergo the test. The third patient (patient 11) was excluded
from the study because she did not undergo phase C. Eight
patients were in functional class I in regard to oxygen con-
sumption; 1 patient had data compatible with functional
class III in the postplacebo phase. This phase had the
lowest levels of maximum V0
2
; however, a significant diffe-
rence between the prestudy data and those after phases A,
B, or C did not exist. Maximum V0
2
 values in the different
groups were as follows: 33±8.4 (20 – 46.6) in the prestudy
examination; 32.5±5.5 (27.4 – 41.3) in phase A; 31±6.4 (24.6 –
43.6) in phase B; 34.8±10.8 (19.3 – 55.7) in phase C; and
25.4±7.6 (10.3 – 36.2) in phase D. The anaerobic threshold
values were as follows: 25±5.1 (16.3 – 33.6) in the prestudy
examination; 25.7±6.2 (15.9 – 33.3) in phase A; 22.5±6.1 (16.1
– 36.8) in phase B; 25.3±4.7 (16.3 – 32.6) in phase C; and
18.7±5.2 (7.9 – 25.9) in phase D.
The inter- and intraobserver correlation coefficients of
the linear regression analysis were, respectively, 0.98 and
0.98 for left ventricular diastolic diameter; 0.99 and 0.97 for
left ventricular systolic diameter; 0.99 and 0.99 for left atrial
area; 0.98 and 0.97 for the regurgitant jet area; 0.95 and 0.98
for the aortic root measurement; 0.99 and 0.99 for the integral
of time and velocity of the aortic flow; 0.92 and 0.94 for the
dt measurement; and 0.94 and 0.98 for the h measurement.
Discussion
Several indices have been proposed to assess left ven-
tricular systolic function in patients with chronic mitral
regurgitation with the purpose of analyzing the contractile
function closely related to other factors, such as preload,
afterload, and heart rate.
No previous study exists analyzing the behavior of the
echocardiographic parameters of left ventricular systolic
function under pharmacological intervention with digitalis
and enalapril in asymptomatic children and adolescents
with mitral regurgitation and hemodynamic repercussion
with preserved left ventricular systolic function.
Table II – Mean values of the parameters analyzed distributed in the different phases, before (pre) and after (post) pharmacological intervention
          A           B          C          D
Pre Post Pre Post Pre Post Pre Post
HR 81.7 81.6 86.1 82.9 83.8 81.5 85.1 85.1
SBP 115.4 115.8 113.3 112.1 117.1 112.9 116.2 114.6
DBP 74.2 76.7 73.3 72.9 79.2 73.8 77.9 76.7
MBP 87.9 89.7 86.7 86 91.7 86.7 90.8 89.1
LVDD 59.3 58.8 59.1 59.3 59.3 58.9 59 58.8
LVSD 37 35.9** 37.2 36.3** 37.8 35.8** 37.3 37.4
DD% 37.5 38.9 37 38.8** 36.3 39.2** 36.9 36.3
EF% 66.3 68.7* 66 68.3** 65.3 69** 65.9 65.3
ESWS 86 76.3** 86.7 78.5** 91.8 73.3** 86.4 91.3
Wss 170.5 154.2** 170.9 157.5** 180.1 149.6** 170.6 178.6
dP/dt 1180.6 1592.6** 998 1157.5** 1042.4 1409** 1203.5 1179
RF 27 24.9* 28.3 25.2 25.3 23 25.8 25.3
RJA 6.4 5.6* 6.7 6.1 6.1 5.6 6.1 6.1
SV 45.8 49.1* 45.8 47.6 45.7 47.8 48.3 46
HR- heart rate in beat/min; SBP- systolic blood pressure; DBP- diastolic blood pressure; MBP- mean blood pressure in mm Hg; LVDD- left ventricular diastolic
diameter in mm; LVSD- left ventricular systolic diameter in mm; DD%- left ventricular shortening fraction in %; EF%- left ventricular ejection fraction %; ESWS- left
ventricular end-systolic meridional wall stress in g/cm2; Wss- left ventricular end-systolic wall stress in mmHg; dP/dt- incremental rate of LV pressure in respect to
time in mm Hg/s; RF- regurgitant fraction in %; RJA- regurgitant jet area in cm2; SV- left ventricular stroke volume in cm3.  * P £ 0.05  ** P£ 0.01.
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Chronic mitral regurgitation causes volume overload
in left chambers with a consequent increase in the preload
conditions, which favors their performance through the
Frank-Starling mechanism. Because part of the stroke volu-
me is ejected to a low-pressure and high-compliance cham-
ber, such as the left atrium, afterload in this situation is low
or normal, being increased only in later periods of the
disease evolution, when, despite these favorable condi-
tions, the left ventricle has difficulty in ejecting its volume
due to the systolic dysfunction. At this moment, heart fai-
lure becomes manifest with appearance of the symptoms
due to low output and pulmonary congestion.
Several studies were carried out with patients with
heart failure and mitral regurgitation, aiming at analyzing the
clinical improvement of patients, ie, an improvement in
functional class or a reduction in mortality at the long run, or
both 3,4,24. Although repercussion in functional class is very
important in the clinical follow-up, by definition it is
unfeasible in asymptomatic patients.
In the present study, the behavior of some echocardio-
graphic parameters of ventricular function under inotropic
and vasodilating pharmacological action was analyzed in
mildly symptomatic patients with chronic mitral regurgitation
and normal ejection fraction at the beginning of the protocol.
The clinical data showed no significant variation in
heart rate or blood pressure during the study. Because left
ventricular diastolic diameter showed no significant varia-
tion in the different phases, preload was considered stable
during the study. Although some studies have shown a re-
duction in diastolic diameter after the use of some vasodila-
tors 7,11,13, no changes in these parameters were observed in
adults with cardiomyopathy receiving captopril and place-
bo 3, in patients with significant mitral regurgitation after a
single dose 6 or prolonged use 12 of captopril, in adults with
mitral regurgitation secondary to mitral valvular prolapse
receiving ramipril 9, and in healthy individuals after digoxin
administration 5.
Left ventricular end-systolic diameter decreased sig-
nificantly in the phases in which digoxin and enalapril were
administered, with no variation in the placebo phase (D).
Both the shortening and ejection fractions, as well as
mean dP/dt, increased in the phases with drug administra-
tion, indicating an improvement in the parameters of ventri-
cular function, a totally different behavior from that obser-
ved with placebo administration. Because preload remained
unaltered, we believe that this was due to an increase in con-
tractility with the use of digoxin and to a probable reduction
in afterload with the use of enalapril. This may somehow be
confirmed by the reduction in left ventricular wall stress ob-
served in the groups receiving medication.
The forward systolic volume ejected from the left ven-
tricle per heartbeat is another parameter indicative of left ven-
tricular systolic function. Considering that this is the result of
the difference between the diastolic and systolic ventricular
volumes for each level of contractility, it has a direct correla-
tion with preload and an inverse correlation with afterload. In
normal situations, this volume is totally ejected in the aorta
and constitutes the forward stroke volume.
In mitral regurgitation, a great part of the stroke volume
flows back to the left atrium, and the forward stroke volume
has an inverse relation with the mitral regurgitation volume.
Considering that approximately half of the mitral regurgita-
tion occurs prior to the aortic valve opening 25, both the left
ventricular end-systolic volume and the forward stroke vo-
lume are decreased in mitral regurgitation. In the present
study, an increase in stroke volume was observed in the
phases with drug administration, and a mild reduction was
observed in the placebo phase; however, only the phase
with digoxin showed a statistically significant increase. The
mitral regurgitant fraction was also reduced in the phases
with drug administration, and this reduction was significant
only in the phase with digoxin.
Although it was previously proposed that the size of
the regurgitant orifice diminished in situations with increa-
sed ventricular contractility or reduced intraventricular vo-
lume 26,27, or both, this theory could not explain our results,
because the velocity of the jet and not the regurgitation
volume was the factor determining the size of the regurgitant
area in color flow mapping 28. Based on this, the mechanism
of the difference observed between digoxin and enalapril
could be explained by the capacity of the former to reduce
the systolic preejection period 29,30. Knowing that, in the
presence of mitral regurgitation, the left ventricular forward
stroke volume is inversely correlated with the mitral regurgi-
tation volume, and considering that regurgitation occurs
mainly in the systolic preejection phase 25, a reduction in this
period with digoxin may play an important role in regurgita-
tion reduction, because it reduces the time in which regurgi-
tation is more intense. Later on, with the aortic valve opening
and a reduction in left ventricular systolic diameter, a reduc-
tion in the regurgitant orifice and an increase in the regur-
gitation velocity occur. At that moment, however, a great part
of the intraventricular volume is also ejected into the aorta,
diminishing the regurgitation volume, and, therefore, the
velocity of the regurgitant jet. Considering that no significant
variation in heart rate was observed, the reduction in the
preejection period should be followed by an increase in the
systolic ejection period. This mechanism could explain both
the reduction in the valvular regurgitation and the increase
in the stroke volume in patients with mitral regurgitation and
preserved ventricular function with the use of digoxin.
The reduction in mitral regurgitation with the use of
vasodilators was previously cited in patients with cardio-
myopathy after receiving captopril for 8 to 12 weeks 3, and
also in adults with significant mitral regurgitation receiving
quinapril 7,13, losartan 8, and ramipril 9. We believe that the
mild variations here observed could achieve statistical
significance in larger population samples.
Because previous studies do not exist indicating that
the systolic preejection period may be altered by enalapril,
unlike that which occurs with digoxin, the reduction in the
regurgitation volume with enalapril should occur mainly in
the systolic ejection period, when the reduction in afterload
may favor a mild increase in left ventricular stroke volume
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however, may be attenuated by the significant regurgitation
of the preejection phase. Based on this, both the mitral
regurgitation velocity, which determines the regurgitant jet
area, and the stroke volume could be little altered.
The cardiopulmonary exercise test may help to charac-
terize the functional class of the patients with mitral regurgi-
tation. Of the 2 patients classified as functional class II on
clinical evaluation who underwent the test, 1 had V0
2
 con-
sumption levels compatible with functional class I and the
other had them compatible with functional class III on the
test performed after the use of placebo. This small number of
patients does not allow conclusions about the mechanism
involved in this difference between the clinical evaluation
and that resulting from the cardiopulmonary exercise test.
The last patient, however, had a worse left ventricular per-
formance measured on echocardiography as compared with
those of the other patients.
In this study, we observed an improvement in the para-
meters studied with the use of digoxin and enalapril. Al-
though digoxin proved to be superior in some results, both
were considered effective for this purpose, and the combi-
nation of the drugs showed no additional effect.
New studies should be carried out to elucidate whe-
ther the improvement in the parameters of ventricular func-
tion have beneficial effects on the long-term evolution of
these patients, mainly considering the survival or evolution
to surgical treatment, or both. As previously cited, patients
with chronic mitral regurgitation may have an irreversible
silent myocardial dysfunction 31. Based on this, we curren-
tly do not know whether the treatment with digoxin or enala-
pril, or both, may beneficially delay the appearance of that
dysfunction or mask its beginning or its evolution, or both,
becoming, in this case, deleterious to the patient’s evolution.
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